Furthermore, hepatic response to FGF19 seemed to be impaired in humans with NAFLD (190) and lack of FGF19 and decreased FGF19 activity may worsening NASH due to accumulation of toxic bile acids. Here, FGF19 is linked to metabolic dysfunction-associated steatotic liver disease.